Drug Trial Radar · NCT07612137
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
282
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.
Conditions
- Solid Tumor
Interventions
IBI3005Drug
Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
SintilimabDrug
Anti-PD-1 Monoclonal Antibody
Bevacizumab biosimilarDrug
Recombinant humanized anti-VEGF monoclonal antibody
LimertinibDrug
Third-generation EGFR-TKI
OsimertinibDrug
Third-generation EGFR-TKI
CarboplatinDrug
Second-generation platinum-based chemotherapy drugs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse eventsTime frame: Up to 3 years
- Number of subjects with treatment emergent adverse eventsTime frame: Up to 3 weeks
- Number of subjects with adverse events of special interestTime frame: Up to 3 years
- Number of subjects with serious adverse eventsTime frame: Up to 3 years
- Dose limiting toxicities (DLTs)Time frame: Up to 3 weeks
- Number of subjects with clinically significant changes in laboratory tests resultsTime frame: Up to 3 years
- Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 3 years
- Number of subjects with clinically significant changes in vital signsTime frame: Up to 3 years
- Objective Response Rate, (ORR)Time frame: Up to 3 years
- duration of response (DCR)Time frame: Up to 3 years
- time to response (TTR)Time frame: Up to 3 years
- duration of response (DoR)Time frame: Up to 3 years
- progression free survival (PFS)Time frame: Up to 3 years
- overall survival (OS)Time frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SunYat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.